Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Diabetes research investment in the European Union

Nature Medicine volume 12, pages 70–72 (2006)Cite this article

It is astonishing that, in our times, a noncommunicable disease should have acquired the cursed label of pandemic, yet such is the situation for diabetes. The numbers speak for themselves, with up to 200 million people worldwide currently suffering from the disease and the prediction that this number will double by the year 2025. In addition to the decreased life expectancy and lower quality of life of individuals with diabetes, the disease and its associated complications are a major burden on national budgets.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Support earmarked for academic diabetes research in 2004.
Figure 2: Percentage of articles in the journal Diabetes according to country or region of origin for the period 2001–2004.

Acknowledgements

The authors declare they have links with the organizations mentioned in this article. P.A.H. is immediate former president of the EASD/EFSD and is currently chairman of the EFSD Advisory Board and of EURADIA. E.F. is the current president of the EASD/EFSD. J.N. is a former president of the EASD/EFSD and currently a senior advisor to EFSD. This article reflects their personal opinions and not those of these organizations.

Author information

Authors and Affiliations

  1. Department of Genetic Medicine and Development, University Medical Centre, 1 rue Michel-Servet, Geneva, 1211 4, Switzerland

    Philippe A Halban

  2. Department of Internal Medicine and CNR Institute of Clincal Physiology, Metabolism Unit, University of Pisa, School of Medicine via Rome, 67, Pisa, I-56100, Italy

    Ele Ferrannini

  3. Steno Diabetes Centre, Niels Steensensvej 2, Gentofte, 2820, Denmark

    Jørn Nerup

Authors
  1. Philippe A Halban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ele Ferrannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jørn Nerup
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe A Halban.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halban, P., Ferrannini, E. & Nerup, J. Diabetes research investment in the European Union. Nat Med 12, 70–72 (2006). https://doi.org/10.1038/nm0106-70

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0106-70

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing